<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03152565</url>
  </required_header>
  <id_info>
    <org_study_id>GEMCAD-1602</org_study_id>
    <secondary_id>2016-003838-24</secondary_id>
    <nct_id>NCT03152565</nct_id>
  </id_info>
  <brief_title>Avelumab Plus Autologous Dendritic Cell Vaccine in Pre-treated Metastatic Colorectal Cancer Patients</brief_title>
  <acronym>AVEVAC</acronym>
  <official_title>A Single Arm Phase I-II Multicenter Trial With Avelumab Plus Autologous Dendritic Cell Vaccine to Determine Safety and Preliminary Efficacy of the Combination in Pre-treated Mismatch Repair-proficient (MSS) Metastatic Colorectal Cancer Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Espanol Multidisciplinario del Cancer Digestivo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Espanol Multidisciplinario del Cancer Digestivo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single arm Phase I/II multicentric open labeled, with translational sub-study, of avelumab&#xD;
      plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS)&#xD;
      metastatic colorectal cancer patients..&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This 2-phases study will first evaluate two different doses/schema of avelumab plus&#xD;
      autologous dendritic cell vaccine (ADC) vaccines, in intention to define which dose is&#xD;
      effective without hampering safety. Second phase will consist in an standard analysis of&#xD;
      efficacy and progression free survival. It is expected that 4 Spanish Sites will include&#xD;
      patients in phase I and 8 Spanish Centers will include patients in the phase II of the study&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 12, 2018</start_date>
  <completion_date type="Actual">October 5, 2020</completion_date>
  <primary_completion_date type="Actual">June 30, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose of Avelumab in combination with Autologous Dendritic Cells</measure>
    <time_frame>18 months</time_frame>
    <description>Dose of avelumab at which no dose limiting toxicity is shown.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of patients without progression of disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>18 months</time_frame>
    <description>Frequency, nature and number of patients developing adverse events throughout follow up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Consensus Molecular Subtypes' (CMS) classification of Immunophenotype signature in tumor biopsies before and during treatment.</measure>
    <time_frame>18 months</time_frame>
    <description>Modified CMS classification by NanoString</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunophenotype signature in tumor biopsies before and during treatment.</measure>
    <time_frame>18 months</time_frame>
    <description>MSS, RAS and BRAF mutation status at baseline and during treatment.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Colorectal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Avelumab in combination ADC vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in both phases will receive Avelumab biweekly intravenous during a maximum of 12 months and biweekly 10x106 ADC vaccine (intradermal) for five doses (days 1, 14, 28, 42 and 56) followed by a maximum of 6 doses every 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Avelumab</intervention_name>
    <description>Autologous Dendritic Cells vaccine: A dose of ADC at days 1, 14, 28, 42 and 56 (total of 5 doses), and thereafter every 6 months until disease progression (maximum of 6 additional doses) or unacceptable toxicity.&#xD;
Avelumab will be administered intravenously at a dose of 10 mg per kilogram of body weight, every 14 days until disease progression or unacceptable toxicity.</description>
    <arm_group_label>Avelumab in combination ADC vaccine</arm_group_label>
    <other_name>Autologous Dendritic Cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent of approved by the investigator's Institutional Review Board&#xD;
             (IRB)/Independent Ethics Committee (IEC), prior to the performance of any trial&#xD;
             activities.&#xD;
&#xD;
          -  Histological diagnosis of MSS colorectal adenocarcinoma.&#xD;
&#xD;
          -  Metastatic disease treated with at least two chemotherapy line, with or without&#xD;
             targeted therapies.&#xD;
&#xD;
          -  Male or female subjects aged ≥ 18 years.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.&#xD;
&#xD;
          -  Measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1&#xD;
             criteria.&#xD;
&#xD;
          -  Lactate dehydrogenase (LDH) levels (&lt;1.5 ULN) (between 250-450 U/L). Maximum allowed&#xD;
             675 U/L.&#xD;
&#xD;
          -  Adequate hepatic function defined by a total bilirubin level ≤ 1.5 × the upper limit&#xD;
             of normality (ULN) and Aspartate Aminotransferase (AST) and Alanine Aminotransferase&#xD;
             (ALT) levels ≤ 2.5 × ULN or AST and ALT levels ≤ 5 x ULN (for subjects with documented&#xD;
             metastatic disease to the liver).&#xD;
&#xD;
          -  Negative serum pregnancy test at screening for women of childbearing potential.&#xD;
&#xD;
          -  Highly effective contraception for both male and female subjects throughout the study&#xD;
             and for at least 60 days after last avelumab treatment administration if the risk of&#xD;
             conception exists.&#xD;
&#xD;
          -  Adequate hematological function: a) Haemoglobin ≥ 9 g/dL (may have been transfused).&#xD;
&#xD;
             b) Platelet count ≥ 100 × 109/L. c) Absolute neutrophil count (ANC) ≥ 1.5 × 109/L.&#xD;
&#xD;
          -  Renal: Estimated creatinine clearance ≥ 30 mL/min according to the Cockcroft-Gault&#xD;
             formula (or local institutional standard method).&#xD;
&#xD;
          -  Female subjects must either be of non-reproductive potential (ie, post-menopausal by&#xD;
             history: ≥60 years old and no menses for ≥1 year without an alternative medical cause;&#xD;
             OR history of hysterectomy, OR history of bilateral tubal ligation, OR history of&#xD;
             bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with brain metastases.&#xD;
&#xD;
          -  Prior organ transplantation, including allogeneic stem-cell transplantation.&#xD;
&#xD;
          -  Presence of clinical ascites.&#xD;
&#xD;
          -  Modified Charlson score &gt;2 (excluded cancer).&#xD;
&#xD;
          -  Significant acute or chronic infections including, among others: Known history of&#xD;
             testing positive test for human immunodeficiency virus (HIV) or known acquired&#xD;
             immunodeficiency syndrome (AIDS). Positive test for Hepatitis C Virus (HCV) surface&#xD;
             antigen and / or confirmatory Hepatitis C Virus (HCV) Ribonucleic acid (RNA) (if&#xD;
             anti-HCV antibody tested positive).&#xD;
&#xD;
          -  Active autoimmune disease that might deteriorate when receiving an immunostimulatory&#xD;
             agent: a)Subjects with diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid&#xD;
             disease not requiring immunosuppressive treatment are eligible. b) Subjects requiring&#xD;
             hormone replacement with corticosteroids are eligible if the steroids are administered&#xD;
             only for the purpose of hormonal replacement and at doses ≤ 10 mg/24 h of prednisone&#xD;
             or equivalent. c) Administration of steroids through a route known to result in a&#xD;
             minimal systemic exposure (topical, intranasal, intraocular, or inhalation) are&#xD;
             acceptable.&#xD;
&#xD;
          -  Local positive serologic determination to: Hepatitis B surface antigen (HBsAg),&#xD;
             hepatitis B surface antibody (Anti-HBc), Hepatitis B Virus (HBV), Hepatitis C Virus&#xD;
             (HCV), HCV ribonucleic acid test (HCV RNA), HIV-I RNA, Agp24 III-V + Carbonic&#xD;
             anhydrase III-V (CAIII-V) ½ (MLIA) serum, Immunoglobulin G (Ig) antigen core HBV,&#xD;
             reaginic antibodies (RPR) for Systemic Erythematosus Lupus (SEL-RPR) serum,&#xD;
             immunoglobulin G (IgG), cytomegalovirus (EIA), Anti-Human T-Cell Lymphotropic I/II&#xD;
             Viruses (HTLV) Antigens (if patient came from endemic zone), Anti-Trypanosoma Cruzi&#xD;
             antibodies, Chagas (if patient came from endemic zone), when RPR positive or doubtful&#xD;
             for confirmation: IgG Treponema pallidum (ELISA), Immunoglobulin M (IgM) Treponema&#xD;
             pallidum (ELISA), when IgG T. Pallidum doubtful: Pt confirmatory IgG/IgM, Treponema&#xD;
             pallidum (LIA).&#xD;
&#xD;
          -  Known severe hypersensitivity reactions to monoclonal antibodies (Grade ≥ 3 according&#xD;
             National Cancer Institute-Common Terminology for Common Adverse Events/NCI-CTCAE v&#xD;
             4.03), - any history of anaphylaxis, or uncontrolled asthma. Persisting toxicity&#xD;
             related to prior therapy of Grade &gt;1 NCI-CTCAE v 4.03; however, alopecia and sensory&#xD;
             neuropathy Grade ≤ 2 is acceptable.&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
&#xD;
          -  Known alcohol or drug abuse.&#xD;
&#xD;
          -  All other significant diseases (for example, inflammatory bowel disease, uncontrolled&#xD;
             asthma), which, in the opinion of the Investigator, might impair the subject's&#xD;
             tolerance of trial treatment&#xD;
&#xD;
          -  Any psychiatric condition that would impede the understanding of informed consent&#xD;
&#xD;
          -  Vaccination other study treatment is prohibited, within 4 weeks of the first dose of&#xD;
             avelumab and while on trial.&#xD;
&#xD;
          -  History of other tumors in the past 5 years.&#xD;
&#xD;
          -  Active infections.&#xD;
&#xD;
          -  Current immunosuppressive treatment, except for the following: a. intranasal, inhaled,&#xD;
             topical steroids, or local steroid injection (e.g., intra-articular injection); b.&#xD;
             Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent;&#xD;
             c. Steroids as premedication for hypersensitivity reactions (e.g., CT scan&#xD;
             premedication).&quot;&#xD;
&#xD;
          -  Known hypersensitivity to avelumab, ADC vaccines or their components.&#xD;
&#xD;
          -  Legal incapacity or limited legal capacity.&#xD;
&#xD;
          -  Patients with pneumonitis and pulmonary fibrosis.&#xD;
&#xD;
          -  Patients with cardiac medical history: Clinically significant (i.e., active)&#xD;
             cardiovascular disease: cerebral vascular accident/stroke (&lt; 6 months prior to&#xD;
             enrollment), myocardial infarction (&lt; 6 months prior to enrollment), unstable angina,&#xD;
             congestive heart failure (≥ New York Heart Association Classification Class II), or&#xD;
             serious cardiac arrhythmia requiring medication.&#xD;
&#xD;
          -  Female patients who are pregnant or breastfeeding or male or female patients of&#xD;
             reproductive potential who are not willing to employ highly effective birth control&#xD;
             from screening to 180 days after the last dose of ADC + avelumab combination therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joan Maurel Santasusana, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clínic Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08024</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08024</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario y Politécnico La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 11, 2017</study_first_submitted>
  <study_first_submitted_qc>May 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2017</study_first_posted>
  <last_update_submitted>October 5, 2020</last_update_submitted>
  <last_update_submitted_qc>October 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Avelumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

